Showing 7911-7920 of 9459 results for "".
- New Global Initiative Aims to Improve Eczema Carehttps://practicaldermatology.com/news/new-global-initiative-aims-to-improve-eczema-care/2460913/The new Global Patient Initiative to Improve Eczema Care (GPIIEC) is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients with eczema and their caregivers. The global
- World Atopic Eczema Day Focuses on Disease Awarenesshttps://practicaldermatology.com/news/world-atopic-eczema-day-focuses-on-disease-awareness/2460912/As patient communities worldwide join forces to raise awareness about atopic eczema, the International Alliance of Dermatology Patient Organisations (GlobalSkin) and the global atopic eczema community call on healthcare professionals, health policy decision ma
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti
- FDA: Omeza's Collagen Matrix Cleared for Marketinghttps://practicaldermatology.com/news/fda-omezas-collagen-matrix-cleared-for-marketing/2460904/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Omeza Collagen Matrix for chronic wound care. Omeza Collagen Matrix (OCM) is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin pr
- Landmarks and Bridges Go Blue for Alopecia Areata Awareness Monthhttps://practicaldermatology.com/news/landmarks-and-bridges-go-blue-for-alopecia-areata-awareness-month/2460900/Bridges, buildings and other landmarks across the United States will be illuminated blue in recognition of Alopecia Areata Awareness Month this September, The current illumination schedule follows below. Any updates or additions to the schedule will be posted
- Study: Dupixent Improves AD Symptoms in Kids As Young As Six Monthshttps://practicaldermatology.com/news/study-dupixent-improves-ad-symptoms-in-kids-as-young-as-six-months/2460898/Dupixent (dupilumab) significantly reduces signs and symptoms of moderate-to-severe atopic dermatitis in children as young as six months, a new study shows. The trial met its primary and all secondary endpoints, showing that Dupixent added to standard-of-care topical corticosteroids (TC
- Business News: Crown Labs to Acquire StriVectinhttps://practicaldermatology.com/news/business-news-crown-labs-acquire-strivectin/2460897/Crown Laboratories is slated to acquire StriVectin from the private equity firm L Catterton. The transaction is expected to close by mid-September and is subject to regulatory approvals and other customary closing conditions. Terms of the transaction were not disclosed.
- FDA Approves Amendment to Avita's Vitiligo Trial Designhttps://practicaldermatology.com/news/fda-approves-amendment-to-avitas-vitiligo-trial-design/2460893/Avita Medical, Inc. will move forward with an amended pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design, now that the FDA has approved the trial modification. The
- UV Index Today is Helping to Reduce Skin Cancer Rates with Web Technologyhttps://practicaldermatology.com/news/uv-index-today-is-helping-to-reduce-skin-cancer-rates-with-web-technology/2460891/UV Index Today launched their free UV forecasting service to help people track the sun’s ultraviolet radiation
- MoonLake Immunotherapeutics Taps Former Kymab CEO Simon Sturge as Chairman and Spike Loy for the Board of Directorshttps://practicaldermatology.com/news/moonlake-immunotherapeutics-taps-former-kymab-ceo-simon-sturge-as-chairman-and-spike-loy-for-the-board-of-directors/2460887/Simon Sturge is the new Chairman of MoonLake Immunotherapeutics AG, and Spike Loy has joined the Company’s Board of Directors. Mr. Sturge has 40 years of international leadership experience in the biotechnology and pharmaceutical industry. Most recently, he was Chief Ex